These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19411316)

  • 1. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
    Delmonte A; Ghielmini M; Sessa C
    Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
    Cheson BD
    Curr Opin Hematol; 2009 Jul; 16(4):299-305. PubMed ID: 19367159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of mantle cell lymphoma: targeting the microenvironment.
    Drach J; Seidl S; Kaufmann H
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
    Costa LJ
    Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted treatment and new agents in diffuse large B-cell lymphoma.
    Leonard JP; Martin P; Barrientos J; Elstrom R
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S11-6. PubMed ID: 18760704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
    O'Connor OA; Hamlin P
    Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
    Sawas A; Diefenbach C; O'Connor OA
    Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitors in non-Hodgkin's lymphoma.
    Zelenetz A
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S34-6. PubMed ID: 16280110
    [No Abstract]   [Full Text] [Related]  

  • 9. Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
    O'Connor O; Wright J; Moskowitz CH; Muzzy J; MacGregor-Cortelli B; Hamlin P; Straus D; Trehu E; Schenkein DP; Zelenetz AD
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S21-2. PubMed ID: 19791425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel small-molecule therapy of Hodgkin lymphoma.
    Buglio D; Georgakis G; Younes A
    Expert Rev Anticancer Ther; 2007 May; 7(5):735-40. PubMed ID: 17492936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biologically based therapies for Waldenstrom's macroglobulinemia.
    Mitsiades CS; Mitsiades N; Richardson PG; Treon SP; Anderson KC
    Semin Oncol; 2003 Apr; 30(2):309-12. PubMed ID: 12720159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targets for cancer therapy in childhood sarcomas.
    Wachtel M; Schäfer BW
    Cancer Treat Rev; 2010 Jun; 36(4):318-27. PubMed ID: 20223596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New agents in follicular lymphoma.
    Cheson BD
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
    Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
    Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic malignancies: new developments and future treatments.
    Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New trends in non-Hodgkin's lymphoma therapy].
    Mazur G; Wróbel T; Jurczak W; Butrym A
    Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New agents for the treatment of lymphoma.
    Stathis A; Ghielmini M
    Ann Oncol; 2012 Sep; 23 Suppl 10():x92-8. PubMed ID: 22988000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapies for B-cell non-Hodgkin lymphoma.
    Briones J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.